Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Gerald Bryan Pier, Ph.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. D18EQ-015 (Noah Cohen) Mar 1, 2018 - Feb 29, 2020
    Morris Animal Foundation
    Efficacy of Maternal Immunization Against PNAG to Protect Newborn Foals Against Rhodococcus equi Pneumonia
    Role Description: Our objective is to develop a vaccine that can protect foals against pneumonia caused by natural infection with R. equi under field conditions. Our 1st hypothesis (H1) is that maternal vaccination against PNAG can protect foals against intrabronchial infection with virulent R. equi during the 1st week of life. Our 2nd hypothesis (H2) is that this protection is correlated with the transfer of antibodies against PNAG in plasma that fix complement and mediate opsonophagocytic killing of R. equi in macrophages.
    Role: Co-investigator
  2. PIER16GO (gerald Pier) Apr 1, 2016 - Mar 31, 2018
    Cystic Fibrosis Foundation
    Identification of novel P. aeruginosa vaccine antigens for CF
    Role Description: While there have been exciting advances in the treatment of CF in the past few years, chronic lung infections remain a vexing problem that make up the one of the most difficult aspects of care for patients. Vaccines to prevent the infections, particularly for the organism known as Pseudomonas aeruginosa, could greatly improve overall health and protect against lung damage and respiratory problems. However, discovering vaccines is an inexact science, with most of the work done to date following an empiric process with a lot of trial and error, and so, far, in regard to P. aeruginosa, no success. Our research proposal will use the tools of modern biology and genetics to try to expedite the process of discovering antigens by allowing the immune system of an immunized animal to determine which components of the microbe make the best target antigens. After using techniques of rapid and high-level sequencing of DNA and immunology, specific candidate vaccines will be prepared and used to immunize mice to see if the candidate does, indeed, elicit an immune response that protects against lung infection. With the candidates identified it will then be possible to further develop them for human testing, determine if CF patients lack immunity to the vaccine, thus explaining their susceptibility to infection, with the ultimate goal to alter the course of lung disease via successful vaccination.
    Role: PI
  3. (Noah Cohen) Jan 1, 2016 - Dec 31, 2017
    Grayson Jockey Club
    A Novel Vaccine Against Equine Strangles
    Role Description: Objectives: Infectious diseases are leading causes of morbidity and mortality for horses worldwide. Streptococcus equi subspecies equi (SE) causes a highly contagious disease com-monly known as strangles that remains the most frequently diagnosed infectious disease of horses.14,46 Currently-available vaccines have limitations in safety and efficacy. Great need ex-ists for novel approaches that can generate protective immunity against SE. Bacterial surface polysaccharides have been demonstrated to be highly effective as vaccines against multiple bacterial pathogens, and the Pier laboratory has discovered that a conserved one of these, termed poly-N-acetyl glucosamine (PNAG), can be chemically modified to generate protective immunity.6,10 Antibodies against naturally-occurring PNAG are not protective on their own,22,35,36 but by chemically altering the PNAG molecule a glycoform is produced that elicits antibodies that recognize native PNAG and provide protection.10,26 We will evaluate the safety, immuno-genicity and efficacy of a PNAG-based oligosaccharide conjugated to tetanus toxoid (5GlcNH2-TT) vaccine10 to protect horses against strangles (SE-induced upper respiratory tract disease) by carrying out the following specific aims and hypotheses:
    Role: Co-investigator
  4. R01EY016144 (PIER, GERALD B) Jan 1, 2005 - Aug 31, 2019
    Pathogenesis of microbial anterior eye diseases
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Folmar CN, Cywes-Bentley C, Bordin AI, Rocha JN, Bray JM, Kahn SK, Schuckert AE, Pier GB, Cohen ND. In vitro evaluation of complement deposition and opsonophagocytic killing of Rhodococcus equi mediated by poly-N-acetyl glucosamine hyperimmune plasma compared to commercial plasma products. J Vet Intern Med. 2019 May; 33(3):1493-1499. PMID: 31034109.
  2. Landeta C, McPartland L, Tran NQ, Meehan BM, Zhang Y, Tanweer Z, Wakabayashi S, Rock J, Kim T, Balasubramanian D, Audette R, Toosky M, Pinkham J, Rubin EJ, Lory S, Pier G, Boyd D, Beckwith J. Inhibition of Pseudomonas aeruginosa and Mycobacterium tuberculosis disulfide bond forming enzymes. Mol Microbiol. 2019 Apr; 111(4):918-937. PMID: 30556355.
    Citations:    Fields:    
  3. Ramos Y, Rocha J, Hael AL, van Gestel J, Vlamakis H, Cywes-Bentley C, Cubillos-Ruiz JR, Pier GB, Gilmore MS, Kolter R, Morales DK. PolyGlcNAc-containing exopolymers enable surface penetration by non-motile Enterococcus faecalis. PLoS Pathog. 2019 02; 15(2):e1007571. PMID: 30742693.
  4. Rocha JN, Dangott LJ, Mwangi W, Alaniz RC, Bordin AI, Cywes-Bentley C, Lawhon SD, Pillai SD, Bray JM, Pier GB, Cohen ND. PNAG-specific equine IgG1 mediates significantly greater opsonization and killing of Prescottella equi (formerly Rhodococcus equi) than does IgG4/7. Vaccine. 2019 Feb 21; 37(9):1142-1150. PMID: 30691984.
    Citations:    Fields:    
  5. Liang X, Gupta K, Quintero JR, Cernadas M, Kobzik L, Christou H, Pier GB, Owen CA, Çataltepe S. Macrophage FABP4 is required for neutrophil recruitment and bacterial clearance in Pseudomonas aeruginosa pneumonia. FASEB J. 2019 Mar; 33(3):3562-3574. PMID: 30462529.
    Citations:    Fields:    
  6. Cywes-Bentley C, Rocha JN, Bordin AI, Vinacur M, Rehman S, Zaidi TS, Meyer M, Anthony S, Lambert M, Vlock DR, Giguère S, Cohen ND, Pier GB. Antibody to Poly-N-acetyl glucosamine provides protection against intracellular pathogens: Mechanism of action and validation in horse foals challenged with Rhodococcus equi. PLoS Pathog. 2018 07; 14(7):e1007160. PMID: 30024986.
    Citations:    Fields:    Translation:AnimalsCells
  7. Zaidi TS, Zaidi T, Pier GB. Antibodies to Conserved Surface Polysaccharides Protect Mice Against Bacterial Conjunctivitis. Invest Ophthalmol Vis Sci. 2018 05 01; 59(6):2512-2519. PMID: 29847658.
    Citations:    Fields:    
  8. Little DJ, Pfoh R, Le Mauff F, Bamford NC, Notte C, Baker P, Guragain M, Robinson H, Pier GB, Nitz M, Deora R, Sheppard DC, Howell PL. PgaB orthologues contain a glycoside hydrolase domain that cleaves deacetylated poly-ß(1,6)-N-acetylglucosamine and can disrupt bacterial biofilms. PLoS Pathog. 2018 04; 14(4):e1006998. PMID: 29684093.
    Citations:    Fields:    Translation:Cells
  9. Stevenson TC, Cywes-Bentley C, Moeller TD, Weyant KB, Putnam D, Chang YF, Jones BD, Pier GB, DeLisa MP. Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies. Proc Natl Acad Sci U S A. 2018 04 03; 115(14):E3106-E3115. PMID: 29555731.
    Citations: 2     Fields:    Translation:AnimalsCellsPHPublic Health
  10. Soliman C, Walduck AK, Yuriev E, Richards JS, Cywes-Bentley C, Pier GB, Ramsland PA. Structural basis for antibody targeting of the broadly expressed microbial polysaccharide poly-N-acetylglucosamine. J Biol Chem. 2018 04 06; 293(14):5079-5089. PMID: 29449370.
    Citations:    Fields:    Translation:HumansCells
  11. van Dissel D, Willemse J, Zacchetti B, Claessen D, Pier GB, van Wezel GP. Production of poly-ß-1,6-N-acetylglucosamine by MatAB is required for hyphal aggregation and hydrophilic surface adhesion by Streptomyces. Microb Cell. 2018 Feb 12; 5(6):269-279. PMID: 29850464.
  12. Sanchez-Larrayoz AF, Elhosseiny NM, Chevrette MG, Fu Y, Giunta P, Spallanzani RG, Ravi K, Pier GB, Lory S, Maira-Litrán T. Complexity of Complement Resistance Factors Expressed by Acinetobacter baumannii Needed for Survival in Human Serum. J Immunol. 2017 10 15; 199(8):2803-2814. PMID: 28855313.
    Citations:    Fields: